New diabetes drug retatrutide enters early human testing
NCT ID NCT06982859
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This Phase 1 study tests retatrutide, a new injectable drug, in 95 adults with type 2 diabetes who already take metformin. The goal is to see if retatrutide improves insulin sensitivity and beta-cell function better than placebo or semaglutide over 28 weeks. Participants will receive either retatrutide, semaglutide, or a placebo, and researchers will measure changes in how the body handles sugar.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Profil Institut für Stoffwechselforschung
RECRUITINGNeuss, 41460, Germany
Contact Phone: •••-•••-••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Retatrutide (also known as LY3437943), an injectable drug
What this could lead to
If successful, retatrutide could offer a new treatment option for type 2 diabetes that improves how the body uses insulin and controls blood sugar.
What could go wrong
This is an early Phase 1 trial with only 95 participants, so results may not apply to everyone. The drug may cause side effects or not work better than existing treatments like semaglutide.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.